EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

Ciara Catherine O'Sullivan, Robert Clarke, Matthew Philip Goetz, John Robertson

JAMA Oncology · 01.09.2023 · 9 (9) · 1273

DOI: 10.1001/jamaoncol.2023.2000 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA Oncology, erschienen am 01.09.2023. Verfasst von Ciara Catherine O'Sullivan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Combination therapy with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i: palbociclib, ribociclib, abemaciclib) and endocrine therapy (ET) has been a major advance for the treatment of hormone receptor–positive (HR + ), ERBB2 (formerly HER2)–negative (ERBB2 − ) advanced or metastatic breast cancer. Observations Randomized phase 3 studies demonstrated that the addition of CDK4/6i reduced the hazard risk of disease progression by approximately half compared with hormonal monotherapy (an aromatase inhibitor, tamoxifen, or fulvestrant) in the first-line (1L) and/or second-line (2L) setting. Hence, the US Food and Drug Administration and European Medicines Agency approved 3 CDK4/6i, in both 1L and 2L settings. However, differences among the CDK4/6i regarding mechanisms of action, adverse effect profiles, and overall survival (OS) are emerging. Both abemaciclib and ribociclib have demonstrated efficacy in high-risk HR + early breast cancer. While ET with or without CDK4/6i is accepted as standard treatment for persons with advanced HR + ERBB2 − metastatic breast cancer, several key issues remain. First, why are there discordances in OS in the metastatic setting and efficacy differences in the adjuvant setting? Additionally, apart from HR status, there are few biomarkers predictive of response to CDK4/6i plus ET, and these are not used routinely. Despite the clear OS advantage noted in the 1L and 2L metastatic setting with some CDK4/6i, a subset of patients with highly endocrine-sensitive disease do well with ET alone. Therefore, an unanswered question is whether some patients can postpone CDK4/6i until the 2L setting, particularly if financial toxicity is a concern. Finally, given the lack of endocrine responsiveness following progression on some CDK4/6i, strategies to optimally sequence treatment are needed. Conclusions and Relevance Future research should focus on defining the role of each CDK4/6i in HR + breast cancer and developing a biomarker-directed integration of these agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsBreast NeoplasmsHumansFemaleCyclin-Dependent Kinase 4AminopyridinesErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Protein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsPurinesBenzimidazoles

Substanzen

Cyclin-Dependent Kinase 4AminopyridinesErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Protein Kinase InhibitorsribociclibPurinesabemaciclibBenzimidazolesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Mayo Clinic, Rochester, Minnesota.
  • The Hormel Institute, University of Minnesota Cancer Systems Biology, Austin.
  • Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, St Paul.
  • Department of Pharmacology, Mayo Clinic, Rochester, Minnesota.
  • Graduate Entry Medical School, University Hospitals of Derby and Burton, University of Nottingham, Derby, United Kingdom.

Förderung

  • NCI NIH HHS

Zitieren

APA

O'Sullivan, C. C., Clarke, R., Goetz, M. P., & Robertson, J. (2023). Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer. JAMA Oncology, 9(9), 1273. https://doi.org/10.1001/jamaoncol.2023.2000

Vancouver

O'Sullivan CC, Clarke R, Goetz MP, Robertson J. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer. JAMA Oncology. 2023;9(9):1273. doi:10.1001/jamaoncol.2023.2000

BibTeX
@article{OSullivan2023,
  author = {O'Sullivan, Ciara Catherine and Clarke, Robert and Goetz, Matthew Philip and Robertson, John},
  title = {Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer},
  journal = {JAMA Oncology},
  year = {2023},
  volume = {9},
  number = {9},
  pages = {1273},
  doi = {10.1001/jamaoncol.2023.2000}
}
Kostenlos starten →